TYME Announces Leadership Team Update

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies, announced a realignment in responsibilities among its leadership team. Effective March 15, 2019, Michael Demurjian retired from Tyme as its Chief Operating Officer and member of the Board of Directors; Michele Korfin has taken on the role of Chief Operating Officer; and Jonathan Eckard, Ph.D. has assumed the new role of Chief Business Officer.

“Michael Demurjian announced that he decided to leave TYME after co-founding the Company and being an integral part of its development over the past ten years. Under Michael’s guidance, TYME has moved from the concept stage, to a publicly traded company on the NASDAQ, to today, where our lead compound SM-88 is moving into multiple pivotal studies,” said TYME CEO, Mr. Steven Hoffman. “Michael brought TYME to the point where he can now focus on other endeavors knowing that his vision for TYME will carry on through an accomplished team with a proven industry track record. Thanks to Michael’s many contributions, we are positioned for success as we prepare for our next phase of growth.”

Michele Korfin, who has served as our Chief Commercial Officer since October 2018, will now be assuming the role of Chief Operating Officer. Since joining Tyme, Ms. Korfin has been instrumental with advancing our Corporate and SM-88 Strategy. Ms. Korfin has over 20 years of biotechnology experience, and throughout her career, she has led many different operational functions throughout the biotechnology industry. Ms. Korfin led the global development programs for REVLIMID^® in Lymphoma and CLL, focusing on bridging pre-clinical science, translational medicine, clinical development and overseeing the path to successful regulatory approvals.

Ms. Korfin has also led paradigm changing product launches in hematology and oncology. This included developing the oncology marketing strategy, leading commercial sales and assuring successful market access for novel therapies. Ms. Korfin was instrumental in building high performing teams, including the nationally recognized Celgene Patient Support team. She also has the recent experience of building teams at Kite from the pre-launch stage through to the successful launch of Yescarta^®. 

In her new role, Ms. Korfin will leverage her experience in building high-performance organizations, as well as her successful track record in advancing disease-altering therapies through regulatory development into commercial markets. Ms. Korfin will continue oversight of the commercial strategy and build out. Ms. Korfin holds an MBA from Harvard Business School and a B.S. in Pharmacy from Rutgers University. She is also on the Board of Trustees of BioNJ, the organization that represents the biotechnology industry for New Jersey. 

Jonathan Eckard, Ph.D., who has served as our Chief Scientific Affairs Officer since 2017, now assumes the role of Chief Business Officer. In this new role, Dr. Eckard will lead our scientific business planning strategies and execution of our scientific and technology platforms. Dr. Eckard will oversee the completion of our SM-88 pre-clinical and clinica pharmacology data collection. These are key aspects of the Tyme scientific platform as we embark on our registration trial for SM-88 in Pancreatic Cancer. Before joining Tyme, Dr. Eckard was the Chief Business and Strategy Officer at oncology-focused Sellas Life Sciences. He has over 12 years of financial experience in equity research, bringing important industry insights and comprehensive understanding of the healthcare equity capital markets. Before his career in financial services, Dr. Eckard conducted cancer research and taught at the NYU School of Medicine, from which he earned his Ph.D. in Toxicology and Carcinogenesis. 

About Tyme Technologies
Tyme Technologies, Inc., is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.

Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidate SM-88 and its clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned clinical trials, preliminary data results and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” or “anticipates,” and similar words (including their use in the negative) or by discussions of future matters such as the development and potential commercialization of our lead drug candidate and of other new products, expected releases of interim or final data from our clinical trials, possible collaborations, the timing, scope and objectives of our ongoing and planned clinical trials and other statements that are not historical. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME’s control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, that the information is of a preliminary nature and may be subject to change; uncertainties inherent in research and development, including the ability to achieve clinical study start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final Phase II data may differ from prior study data or preliminary Phase II data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; competitive developments; and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on June 13, 2018, as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission (available at www.sec.gov).

The information contained in this press release is as of its release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

Contact

Ashley R. Robinson
LifeSci Advisors, LLC
617-535-7742
[email protected] 

Source: Tyme Technologies, Inc.

[ Back To TMCnet.com's Homepage ]